-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Akebia Therapeutics (NASDAQ:AKBA) Now Covered by StockNews.com
Akebia Therapeutics (NASDAQ:AKBA) Now Covered by StockNews.com
Research analysts at StockNews.com began coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research note issued on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Separately, HC Wainwright dropped their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research note on Monday, May 16th. Seven equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $1.75.
Get Akebia Therapeutics alerts:Akebia Therapeutics Price Performance
Shares of AKBA opened at $0.44 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 1.30. The company has a market capitalization of $79.99 million, a price-to-earnings ratio of -0.46 and a beta of 1.50. Akebia Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.35. The firm has a 50-day simple moving average of $0.41 and a 200-day simple moving average of $0.76.
Akebia Therapeutics (NASDAQ:AKBA – Get Rating) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.54. Akebia Therapeutics had a negative net margin of 55.04% and a negative return on equity of 197.12%. The company had revenue of $126.76 million during the quarter, compared to analysts' expectations of $49.10 million. During the same period last year, the company posted ($0.51) earnings per share. On average, equities research analysts anticipate that Akebia Therapeutics will post -0.44 earnings per share for the current year.Institutional Trading of Akebia Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of AKBA. Point72 Hong Kong Ltd acquired a new position in shares of Akebia Therapeutics in the 4th quarter valued at $30,000. BNP Paribas Arbitrage SA increased its stake in Akebia Therapeutics by 123.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 50,066 shares during the period. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $40,000. Finally, MetLife Investment Management LLC increased its stake in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 54,389 shares during the period. 31.56% of the stock is owned by hedge funds and other institutional investors.
Akebia Therapeutics Company Profile
(Get Rating)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
Featured Articles
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Research analysts at StockNews.com began coverage on shares of Akebia Therapeutics (NASDAQ:AKBA – Get Rating) in a research note issued on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
斯托克新聞網的研究分析師在週一發佈的一份研究報告中開始報道木通治療公司(納斯達克：AKBA-GET評級)的股票。該經紀公司對這家生物製藥公司的股票設定了“持有”評級。
Separately, HC Wainwright dropped their price objective on shares of Akebia Therapeutics from $2.00 to $1.25 in a research note on Monday, May 16th. Seven equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $1.75.
另外，在5月16日星期一的一份研究報告中，HC Wainwright將木通治療公司的股票目標價從2.00美元下調至1.25美元。根據MarketBeat.com的數據，七位股票研究分析師對該股的評級為持有，該公司目前的平均評級為持有，平均目標價為1.75美元。
Akebia Therapeutics Price Performance
木通治療藥物的價格表現
Shares of AKBA opened at $0.44 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 1.30. The company has a market capitalization of $79.99 million, a price-to-earnings ratio of -0.46 and a beta of 1.50. Akebia Therapeutics has a fifty-two week low of $0.30 and a fifty-two week high of $3.35. The firm has a 50-day simple moving average of $0.41 and a 200-day simple moving average of $0.76.
週一，AKBA的股價開盤報0.44美元。該公司的負債權益比率為0.51，速動比率為1.15，流動比率為1.30。該公司市值為7,999萬美元，市盈率為-0.46，貝塔係數為1.50。木通治療公司的股價跌至0.30美元的52周低點和3.35美元的52周高點。該公司的50日簡單移動均線切入位為0.41美元，200日簡單移動均線切入位為0.76美元。
Institutional Trading of Akebia Therapeutics
木通治療的制度性交易
Several hedge funds and other institutional investors have recently bought and sold shares of AKBA. Point72 Hong Kong Ltd acquired a new position in shares of Akebia Therapeutics in the 4th quarter valued at $30,000. BNP Paribas Arbitrage SA increased its stake in Akebia Therapeutics by 123.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 50,066 shares during the period. GSA Capital Partners LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $39,000. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter worth $40,000. Finally, MetLife Investment Management LLC increased its stake in Akebia Therapeutics by 176.6% during the 1st quarter. MetLife Investment Management LLC now owns 85,186 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 54,389 shares during the period. 31.56% of the stock is owned by hedge funds and other institutional investors.
幾家對衝基金和其他機構投資者最近買賣了AKBA的股票。Point72 Hong Kong Ltd在第四季度收購了木通治療公司的新股份，價值3萬美元。法國巴黎銀行套利公司在第二季度將其在木通治療公司的股份增加了123.7%。法國巴黎銀行套利公司現在持有90,540股這家生物製藥公司的股票，價值3.2萬美元，在此期間又購買了50,066股。GSA Capital Partners LLP在第一季度購買了木通治療公司價值39,000美元的新股份。Mirabella Financial Services LLP在第一季度購買了Akebia治療公司價值4萬美元的新股份。最後，大都會人壽投資管理有限責任公司在第一季度將其在木通治療公司的股份增加了176.6%。大都會人壽投資管理公司現在擁有85,186股這家生物製藥公司的股票，價值61,000美元，在此期間又購買了54,389股。31.56%的股票由對衝基金和其他機構投資者持有。
Akebia Therapeutics Company Profile
木通治療公司簡介
(Get Rating)
(獲取評級)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.
木通治療公司是一家生物製藥公司，專注於腎臟疾病患者治療藥物的開發和商業化。該公司的主要研究產品候選產品是vadustat，這是一種口服療法，正處於第三階段開發，用於治療依賴透析和非透析依賴的成年患者的慢性腎臟疾病(CKD)引起的貧血。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Akebia Therapeutics (AKBA)
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- Here's Why the CPI Report will Dictate the Market Bottom
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- 免費獲取StockNews.com關於木通治療的研究報告(AKBA)
- 電子藝界能扭轉電子遊戲市場的低迷嗎？
- 美元將軍是美國小池塘裏的大魚。
- 以下是CPI報告將決定市場底部的原因
- MarketBeat：回顧一週9/5-9/9
- 為網絡安全股創紀錄的季度做準備
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受木通治療日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對木通治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧